Total Funding
3
16
Total FundingSeries C raised
Growth Score
-8 pts
Heat Score
0 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
332804
Oxagen is a biopharmaceutical company developing small molecule drugs addressing asthma, and chronic allergic and inflammatory conditions.
John Bell: Co-FounderPast Role: University of Oxford, Nuffield Professorship of Clinical Medicine- Mark Payton: CEO
About the Company
Oxagen Limited, a biopharmaceutical company, provides drug discovery and development solutions. It offers molecule drugs for the treatment of asthma, autoimmune disease, inflammatory bowel, psoriasis, allergy, and rheumatoid arthritis diseases. Oxagen Limited was founded in 1997 and is based in Abingdon, the United Kingdom.
